2National cholesterol education program(NCEP) export pand on detection, evaluation, and treatment of high blood cholesterol in adults ( adult treatment panel Ⅲ). Third report of the national cholesterol education program(NCEP) expertpanel on detection, evaluation, and treatment of high blood choleste in adults ( adult treatment panel Ⅲ) final report[ J]. Circulation,2002,106:3 143
2Kajinami K, Takekoshi N. Cholesterol absorption inhibitots in development as potential therapeutics. Expert Opin Investig Drugs ,2002,21 ( 3 ) :831
3Insull W J, Koren M, Davignon J, et al. Efficacy and short-term satety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins,inpatients with combied hyperlipidemia. Atherosclerosis ,2001,157 ( 1 ) : 137
4Stein EA, Isaocsohn JL, Mazzu A, et al. Effect of Bay 13-9952, a microsomal tfiglyceride transfer protein inhibitor on lipids and lipoptotein in dyslipoproteinmic patient. Ciculation, 1999,100( Suppl1 ) : 1342-1343
5Komori T. CETi -1 avant. Curt Opin invest Drugs,2004,5(3) :334-338
6Grand -Perret T, Bouillot A, Perrot A, et al. SCAP ligands are potent new lipid - lowering drugs. Nat Med,2001,7 (12) :249-256
7Davidson M H, Lukacsko P,Sun J X, et al. A multiple-dose pharmacodynamic safety and pharmacokinetic comparison of extend - and - immediate - release formulations of lovastatin. Clin Ther,2002,24( 1 ) : 112
8Capuzzi D M, Guyton J R, Morgan J M, et al. Efficacy and safety of an extended - release niacin (Niaspan) : along term study. Am J Cardiol, 1998, 82 (12) :74
9Keating G M, Ormord D. Micronised fenofibrate:an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs ,2002,62 ( 13 ) : 1909
10Kashyap M L, McGovern M E, BerraK, et al. Long terms safety and efficacy of a once - daily niacin/lovastatin formulation for patiens with dyslipidemia. Am J Cardiol,2002,89 (6) :672
